Cargando…
SPECT Imaging of SST2-Expressing Tumors with (99m)Tc-Based Somatostatin Receptor Antagonists: The Role of Tetraamine, HYNIC, and Spacers
[(99m)Tc]Tc-HYNIC-TOC is the most widely used (99m)Tc-labeled somatostatin receptor (SST) agonist for the SPECT imaging of SST-expressing tumors, such as neuroendocrine tumors. Recently, radiolabeled SST antagonists have shown improved diagnostic efficacy over agonists. (99m)Tc-labeled SST antagonis...
Autores principales: | Gaonkar, Raghuvir Haridas, Wiesmann, Fabius, Del Pozzo, Luigi, McDougall, Lisa, Zanger, Sandra, Mikołajczak, Renata, Mansi, Rosalba, Fani, Melpomeni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065591/ https://www.ncbi.nlm.nih.gov/pubmed/33800582 http://dx.doi.org/10.3390/ph14040300 |
Ejemplares similares
-
The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist
por: Abiraj, Keelara, et al.
Publicado: (2018) -
Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides
por: Millul, Jacopo, et al.
Publicado: (2023) -
Evaluation of a New (177)Lu-Labeled Somatostatin Analog for the Treatment of Tumors Expressing Somatostatin Receptor Subtypes 2 and 5
por: Mansi, Rosalba, et al.
Publicado: (2020) -
A new (68)Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting
por: Mansi, Rosalba, et al.
Publicado: (2020) -
Selection of the First (99m)Tc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates
por: Fani, Melpomeni, et al.
Publicado: (2020)